Chief Business Officer
Mahen Gundecha leads corporate strategy, global business development and corporate communications for Exegenesis Bio. Mahen also leads the formation of strategic partnerships across all areas of our business, including R&D, manufacturing and commercialization.
Mahen brings a depth of strategic, commercial and operational experience in biotechnology and cell and gene therapy to Exegenesis Bio, with previous leadership experience at Novo Nordisk, Novartis/Sandoz, Juno Therapeutics and emerging biotechnology and cell and gene therapy companies.
Mahen has led business development transactions in neurosciences, oncology and rare diseases, has managed large-scale strategic partnerships in cell and gene therapy and has guided corporate strategy for emerging biotechnology companies.
Mahen Gundecha and his team are responsible for licensing and acquiring innovative technologies to support our development and manufacturing activities, identifying novel clinical programs to enhance our pipeline and forming strategic partnerships to accelerate our growth.
Mahen holds BSc (Biology), BSc (Finance) and MBA (International Business) degrees from leading global universities.